JP2018521629A - 自殺リスクに関する遺伝マーカーおよび関連する方法 - Google Patents

自殺リスクに関する遺伝マーカーおよび関連する方法 Download PDF

Info

Publication number
JP2018521629A
JP2018521629A JP2017559528A JP2017559528A JP2018521629A JP 2018521629 A JP2018521629 A JP 2018521629A JP 2017559528 A JP2017559528 A JP 2017559528A JP 2017559528 A JP2017559528 A JP 2017559528A JP 2018521629 A JP2018521629 A JP 2018521629A
Authority
JP
Japan
Prior art keywords
risk
snps
ssb
genotype
person
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017559528A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018521629A5 (https=
Inventor
ザイ，クレメント・シー
ケネディ，ジェームズ・エル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre for Addiction and Mental Health
Original Assignee
Centre for Addiction and Mental Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre for Addiction and Mental Health filed Critical Centre for Addiction and Mental Health
Publication of JP2018521629A publication Critical patent/JP2018521629A/ja
Publication of JP2018521629A5 publication Critical patent/JP2018521629A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/40—Population genetics; Linkage disequilibrium
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B99/00—Subject matter not provided for in other groups of this subclass
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Ecology (AREA)
  • Physiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2017559528A 2015-05-15 2015-11-19 自殺リスクに関する遺伝マーカーおよび関連する方法 Pending JP2018521629A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CA2891830A CA2891830A1 (en) 2015-05-15 2015-05-15 Genetic markers for suicide risk and related methods
CA2,891,830 2015-05-15
PCT/CA2015/051206 WO2016183659A1 (en) 2015-05-15 2015-11-19 Genetic markers for suicide risk and related methods

Publications (2)

Publication Number Publication Date
JP2018521629A true JP2018521629A (ja) 2018-08-09
JP2018521629A5 JP2018521629A5 (https=) 2019-01-17

Family

ID=57298829

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017559528A Pending JP2018521629A (ja) 2015-05-15 2015-11-19 自殺リスクに関する遺伝マーカーおよび関連する方法

Country Status (7)

Country Link
US (1) US11104952B2 (https=)
EP (1) EP3294902A4 (https=)
JP (1) JP2018521629A (https=)
CA (2) CA2891830A1 (https=)
HK (1) HK1252429A1 (https=)
IL (1) IL255653A (https=)
WO (1) WO2016183659A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10395759B2 (en) 2015-05-18 2019-08-27 Regeneron Pharmaceuticals, Inc. Methods and systems for copy number variant detection
CA3014292A1 (en) 2016-02-12 2017-08-17 Regeneron Pharmaceuticals, Inc. Methods and systems for detection of abnormal karyotypes

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006518206A (ja) * 2003-02-21 2006-08-10 ノバルティス アクチエンゲゼルシャフト 処置中の自殺傾向を予測するための方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6716810B1 (en) * 1998-12-09 2004-04-06 Eleanor Roosevelt Institute Composition and method for regulation of body weight and associated conditions
USH2191H1 (en) 2000-10-24 2007-06-05 Snp Consortium Identification and mapping of single nucleotide polymorphisms in the human genome
US7361468B2 (en) 2004-07-02 2008-04-22 Affymetrix, Inc. Methods for genotyping polymorphisms in humans
WO2006102476A2 (en) * 2005-03-21 2006-09-28 Vicus Therapeutics Spe 1, Llc Compositions and methods for ameliorating cachexia
US7906283B2 (en) * 2006-10-27 2011-03-15 The United States Of America As Represented By The Department Of Health And Human Services Methods to identify patients at risk of developing adverse events during treatment with antidepressant medication
US20120094855A1 (en) * 2008-09-18 2012-04-19 Max Planck Society Means and methods for diagnosing predisposition for treatment emergent suicidal ideation (tesi)
EP2166112B1 (en) 2008-09-18 2013-06-05 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Means and methods for diagnosing predisposition for treatment emergent suicidal ideation
KR101249635B1 (ko) 2010-10-13 2013-04-01 서울대학교산학협력단 양극성 장애 진단용 ｅｇｒ2 유전자 ｓｎｐ, 그를 포함하는 마이크로어레이 및 키트
CN106062213A (zh) 2013-12-23 2016-10-26 戒毒及精神卫生中心 与自杀风险关联的遗传标志物及其使用方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006518206A (ja) * 2003-02-21 2006-08-10 ノバルティス アクチエンゲゼルシャフト 処置中の自殺傾向を予測するための方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J PSYCHIATRIC RESEARCH, 2015, VOL.65, P.23-29, EPUB 2014 NOV 20, JPN6019037467, ISSN: 0004296147 *

Also Published As

Publication number Publication date
IL255653A (en) 2018-01-31
EP3294902A1 (en) 2018-03-21
CA2985841A1 (en) 2016-11-24
WO2016183659A1 (en) 2016-11-24
US11104952B2 (en) 2021-08-31
HK1252429A1 (zh) 2019-05-24
US20180355431A1 (en) 2018-12-13
EP3294902A4 (en) 2018-09-26
CA2891830A1 (en) 2016-11-15

Similar Documents

Publication Publication Date Title
Saw et al. Chromosome 1q21. 2 and additional loci influence risk of spontaneous coronary artery dissection and myocardial infarction
Nagel et al. Item-level analyses reveal genetic heterogeneity in neuroticism
Strawbridge et al. Genome-wide analysis of self-reported risk-taking behaviour and cross-disorder genetic correlations in the UK Biobank cohort
Ratanatharathorn et al. Epigenome‐wide association of PTSD from heterogeneous cohorts with a common multi‐site analysis pipeline
Dumas et al. DUF1220-domain copy number implicated in human brain-size pathology and evolution
Allen-Brady et al. Significant linkage evidence for a predisposition gene for pelvic floor disorders on chromosome 9q21
Lin et al. Genome-wide association studies in pharmacogenomics of antidepressants
Moreau et al. Brain functional connectivity mirrors genetic pleiotropy in psychiatric conditions
Roostaei et al. Proximal and distal effects of genetic susceptibility to multiple sclerosis on the T cell epigenome
van Tilburg et al. A genetic polymorphism that is associated with mitochondrial energy metabolism increases risk of fibromyalgia
Mohandas et al. Evidence for type-specific DNA methylation patterns in epilepsy: a discordant monozygotic twin approach
Davis et al. A third linear association between Olduvai (DUF1220) copy number and severity of the classic symptoms of inherited autism
Dimova et al. Association of genetic and psychological factors with persistent pain after cosmetic thoracic surgery
Khan et al. Combining transdiagnostic and disorder-level GWAS enhances precision of psychiatric genetic risk profiles in a multi-ancestry sample
Schjeide et al. GAB2 as an Alzheimer disease susceptibility gene: follow-up of genomewide association results
Seidlitz et al. The molecular genetic landscape of human brain size variation
Kember et al. Cross-ancestry meta-analysis of opioid use disorder uncovers novel loci with predominant effects on brain
JP2018521629A (ja) 自殺リスクに関する遺伝マーカーおよび関連する方法
Bigdeli et al. Biological insights into schizophrenia from ancestrally diverse populations
Tonozzi et al. Pharmacogenetic profile and major depressive and/or bipolar disorder treatment: a retrospective, cross-sectional study
Lane et al. Biological and clinical insights from genetics of insomnia symptoms
Mondragon-Estrada et al. Noncoding variants and sulcal patterns in congenital heart disease: Machine learning to predict functional impact
Tinkle et al. Human genomics: Challenges and opportunities
Zhou et al. Genotype‐by‐sex interaction analyses for alcohol use disorder across biobanks
JP2020500037A (ja) オピオイド中毒を治療するための方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180316

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181113

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181113

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190930

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200226

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200630